Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Prevalence of isolated antibody to hepatitis B core antigen in an area endemic for hepatitis B virus infection: Implications in hepatitis B vaccination programs

Prevalence of isolated antibody to hepatitis B core antigen in an area endemic for hepatitis B... Of 1,801 Chinese subjects, age 1 to 90 years, screened for hepatitis B surface antigen and antibody (HBsAg, anti‐HBs) and antibody to hepatitis B core antigen (anti‐HBc), 214 (11.9%) had an isolated, positive anti‐HBc result; anti‐HBc was reproducibly present in the initial sera in only 66% and persisted after an interval of 2 weeks to 3 months in only 73%. There was a strong correlation between the rates of reproducibility and persistence of isolated anti‐HBc and the initial anti‐HBc titers. Thirty‐two subjects with persistent, isolated anti‐HBc received four doses of hepatitis B vaccine (5 μg, HEVAC B) at 0, 1, 2 and 12 months: 56% developed a primary anti‐HBs response in response to hepatitis B vaccine, 16% developed an anamnestic or secondary anti‐HBs response, and 28% were undetectable for anti‐HBs even after four doses of vaccine. The low rates of reproducibility and persistence of anti‐HBc together with the high rate of primary anti‐HBs response to hepatitis B vaccine in subjects with isolated anti‐HBc raise doubts as to the reliability of anti‐HBc (Corzyme, Abbott Laboratories, North Chicago, Ill.) as a single screening test for hepatitis B infection prior to vaccination and suggests that subjects with isolated anti‐HBc, in particular those with low anti‐HBc titers, be included in vaccination programs. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Hepatology Wiley

Prevalence of isolated antibody to hepatitis B core antigen in an area endemic for hepatitis B virus infection: Implications in hepatitis B vaccination programs

Lok, Anna S. F.; Lai, Ching‐Lung; Wu, Pui‐Chee
Hepatology , Volume 8 (4) – Jul 1, 1988
Download PDF
5 pages

Loading next page...
 
/lp/wiley/prevalence-of-isolated-antibody-to-hepatitis-b-core-antigen-in-an-area-wsbgioz4Jn

References (34)

Publisher
Wiley
Copyright
Copyright © 1988 American Association for the Study of Liver Diseases
ISSN
0270-9139
eISSN
1527-3350
DOI
10.1002/hep.1840080411
Publisher site
See Article on Publisher Site

Abstract

Of 1,801 Chinese subjects, age 1 to 90 years, screened for hepatitis B surface antigen and antibody (HBsAg, anti‐HBs) and antibody to hepatitis B core antigen (anti‐HBc), 214 (11.9%) had an isolated, positive anti‐HBc result; anti‐HBc was reproducibly present in the initial sera in only 66% and persisted after an interval of 2 weeks to 3 months in only 73%. There was a strong correlation between the rates of reproducibility and persistence of isolated anti‐HBc and the initial anti‐HBc titers. Thirty‐two subjects with persistent, isolated anti‐HBc received four doses of hepatitis B vaccine (5 μg, HEVAC B) at 0, 1, 2 and 12 months: 56% developed a primary anti‐HBs response in response to hepatitis B vaccine, 16% developed an anamnestic or secondary anti‐HBs response, and 28% were undetectable for anti‐HBs even after four doses of vaccine. The low rates of reproducibility and persistence of anti‐HBc together with the high rate of primary anti‐HBs response to hepatitis B vaccine in subjects with isolated anti‐HBc raise doubts as to the reliability of anti‐HBc (Corzyme, Abbott Laboratories, North Chicago, Ill.) as a single screening test for hepatitis B infection prior to vaccination and suggests that subjects with isolated anti‐HBc, in particular those with low anti‐HBc titers, be included in vaccination programs.

Journal

Hepatology – Wiley

Published: Jul 1, 1988

There are no references for this article.